U.S. Government Owns A Patent On Marijuana?
Tech U.S.
— Jul 25, 2014 Demockery in action, Control favor for pharmacy

us-patent-marijuana-07-25
Patent No. 6630507, held by the United States Department of Health and Human Services, covers the use of cannabinoids for treating a wide range of diseases.

Under U.S. federal law, marijuana is defined as having no medical use. So it might come as a surprise to hear that the government owns one of the only patents on marijuana as a medicine.

The patent (US6630507) is titled “Cannabinoids as antioxidants and neuroprotectants” and was awarded to the Department of Health and Human Services (HHS) in October 2003.

It was filed four years earlier, in 1999, by a group of scientists from the National Institute of Mental Health (NIMH), which is part of the National Institutes of Health (NIH).
What is Patent No. 6630507?

us-marijuana-patent-2

The patent claims exclusive rights on the use of cannabinoids for treating neurological diseases, such as Alzheimer’s, Parkinson’s and stroke, and diseases caused by oxidative stress, such as heart attack, Crohn’s disease, diabetes and arthritis.

Cannabinoids are a diverse class of compounds that include many of the unique compounds found in marijuana. A number of experts, including CNN’s chief medical correspondent Dr. Sanjay Gupta, have noted the contradiction between federal marijuana law and the government’s patent.

“The United States government owns a patent on marijuana as a medical application… So we have a patent through our Department of HHS on marijuana as a therapeutic and we also schedule it as a Schedule I.”

It is easy to think of the patent as a patent on marijuana itself. However, this would be inaccurate, since the patent actually covers non-psychoactive cannabinoids (both synthetic and natural), meaning those that don’t cause a high.

The patent also covers only a specific application of these cannabinoids and not the production or use of marijuana and cannabinoids overall.
The Invention

The patent claims to “provide a new class of antioxidant drugs, that have particular application as neuroprotectants.”

According to the description, the inventors recognized “a previously unanticipated antioxidant property of the cannabinoids in general (and cannabidiol in particular).” Importantly, the patent does not cover cannabinoids that act through cannabinoid pathways, also known as receptors.

“This new found property makes cannabinoids useful in the treatment and prophylaxis of wide variety of oxidation associated diseases, such as ischemic, age-related, inflammatory and autoimmune diseases. The cannabinoids are found to have particular application as neuroprotectants, for example in limiting neurological damage following ischemic insults, such as stroke and trauma, or in the treatment of neurodegenerative diseases, such as Alzheimer’s disease, Parkinson’s disease and HIV dementia.”

CBD and Non-Psychoactive Cannabinoids

us-patent-marijuana-3

The government’s patent does not cover THC, the main ingredient in marijuana. On the other hand, cannabidiol (CBD) is specifically mentioned as an example of a cannabinoid that is covered. The patent describes CBD and other non-psychoactive cannabinoids as superior when taken in higher doses.

“Nonpsychoactive cannabinoids, such as cannabidiol, are particularly advantageous to use because they avoid toxicity that is encountered with psychoactive cannabinoids at high doses.”

According to the description, CBD can be ingested in very large amounts without side effects.

“No signs of toxicity or serious side effects have been observed following chronic administration of cannabidiol to healthy volunteers, even in large acute doses of 700mg/day.”

The patent explains that cannabidiol previously had not been considered useful as a neuroprotectant. However, it cites various studies on cannabidiol as an antiepileptic and as a potential treatment for glaucoma.
Does The U.S. Government Own A Patent On Marijuana?

Tech U.S.
— Jul 25, 2014

us-patent-marijuana-07-25
Patent No. 6630507, held by the United States Department of Health and Human Services, covers the use of cannabinoids for treating a wide range of diseases.

Under U.S. federal law, marijuana is defined as having no medical use. So it might come as a surprise to hear that the government owns one of the only patents on marijuana as a medicine.

The patent (US6630507) is titled “Cannabinoids as antioxidants and neuroprotectants” and was awarded to the Department of Health and Human Services (HHS) in October 2003.

It was filed four years earlier, in 1999, by a group of scientists from the National Institute of Mental Health (NIMH), which is part of the National Institutes of Health (NIH).
What is Patent No. 6630507?

us-marijuana-patent-2

The patent claims exclusive rights on the use of cannabinoids for treating neurological diseases, such as Alzheimer’s, Parkinson’s and stroke, and diseases caused by oxidative stress, such as heart attack, Crohn’s disease, diabetes and arthritis.

Cannabinoids are a diverse class of compounds that include many of the unique compounds found in marijuana. A number of experts, including CNN’s chief medical correspondent Dr. Sanjay Gupta, have noted the contradiction between federal marijuana law and the government’s patent.

“The United States government owns a patent on marijuana as a medical application… So we have a patent through our Department of HHS on marijuana as a therapeutic and we also schedule it as a Schedule I.”

It is easy to think of the patent as a patent on marijuana itself. However, this would be inaccurate, since the patent actually covers non-psychoactive cannabinoids (both synthetic and natural), meaning those that don’t cause a high.

The patent also covers only a specific application of these cannabinoids and not the production or use of marijuana and cannabinoids overall.
The Invention

The patent claims to “provide a new class of antioxidant drugs, that have particular application as neuroprotectants.”

According to the description, the inventors recognized “a previously unanticipated antioxidant property of the cannabinoids in general (and cannabidiol in particular).” Importantly, the patent does not cover cannabinoids that act through cannabinoid pathways, also known as receptors.

“This new found property makes cannabinoids useful in the treatment and prophylaxis of wide variety of oxidation associated diseases, such as ischemic, age-related, inflammatory and autoimmune diseases. The cannabinoids are found to have particular application as neuroprotectants, for example in limiting neurological damage following ischemic insults, such as stroke and trauma, or in the treatment of neurodegenerative diseases, such as Alzheimer’s disease, Parkinson’s disease and HIV dementia.”

CBD and Non-Psychoactive Cannabinoids

us-patent-marijuana-3

The government’s patent does not cover THC, the main ingredient in marijuana. On the other hand, cannabidiol (CBD) is specifically mentioned as an example of a cannabinoid that is covered. The patent describes CBD and other non-psychoactive cannabinoids as superior when taken in higher doses.

“Nonpsychoactive cannabinoids, such as cannabidiol, are particularly advantageous to use because they avoid toxicity that is encountered with psychoactive cannabinoids at high doses.”

According to the description, CBD can be ingested in very large amounts without side effects.

“No signs of toxicity or serious side effects have been observed following chronic administration of cannabidiol to healthy volunteers, even in large acute doses of 700mg/day.”

The patent explains that cannabidiol previously had not been considered useful as a neuroprotectant. However, it cites various studies on cannabidiol as an antiepileptic and as a potential treatment for glaucoma.
Does The U.S. Government Own A Patent On Marijuana?

Tech U.S.
— Jul 25, 2014

us-patent-marijuana-07-25
Patent No. 6630507, held by the United States Department of Health and Human Services, covers the use of cannabinoids for treating a wide range of diseases.

Under U.S. federal law, marijuana is defined as having no medical use. So it might come as a surprise to hear that the government owns one of the only patents on marijuana as a medicine.

The patent (US6630507) is titled “Cannabinoids as antioxidants and neuroprotectants” and was awarded to the Department of Health and Human Services (HHS) in October 2003.

It was filed four years earlier, in 1999, by a group of scientists from the National Institute of Mental Health (NIMH), which is part of the National Institutes of Health (NIH).
What is Patent No. 6630507?

us-marijuana-patent-2

The patent claims exclusive rights on the use of cannabinoids for treating neurological diseases, such as Alzheimer’s, Parkinson’s and stroke, and diseases caused by oxidative stress, such as heart attack, Crohn’s disease, diabetes and arthritis.

Cannabinoids are a diverse class of compounds that include many of the unique compounds found in marijuana. A number of experts, including CNN’s chief medical correspondent Dr. Sanjay Gupta, have noted the contradiction between federal marijuana law and the government’s patent.

“The United States government owns a patent on marijuana as a medical application… So we have a patent through our Department of HHS on marijuana as a therapeutic and we also schedule it as a Schedule I.”

It is easy to think of the patent as a patent on marijuana itself. However, this would be inaccurate, since the patent actually covers non-psychoactive cannabinoids (both synthetic and natural), meaning those that don’t cause a high.

The patent also covers only a specific application of these cannabinoids and not the production or use of marijuana and cannabinoids overall.
The Invention

The patent claims to “provide a new class of antioxidant drugs, that have particular application as neuroprotectants.”

According to the description, the inventors recognized “a previously unanticipated antioxidant property of the cannabinoids in general (and cannabidiol in particular).” Importantly, the patent does not cover cannabinoids that act through cannabinoid pathways, also known as receptors.

“This new found property makes cannabinoids useful in the treatment and prophylaxis of wide variety of oxidation associated diseases, such as ischemic, age-related, inflammatory and autoimmune diseases. The cannabinoids are found to have particular application as neuroprotectants, for example in limiting neurological damage following ischemic insults, such as stroke and trauma, or in the treatment of neurodegenerative diseases, such as Alzheimer’s disease, Parkinson’s disease and HIV dementia.”

CBD and Non-Psychoactive Cannabinoids

us-patent-marijuana-3

The government’s patent does not cover THC, the main ingredient in marijuana. On the other hand, cannabidiol (CBD) is specifically mentioned as an example of a cannabinoid that is covered. The patent describes CBD and other non-psychoactive cannabinoids as superior when taken in higher doses.

“Nonpsychoactive cannabinoids, such as cannabidiol, are particularly advantageous to use because they avoid toxicity that is encountered with psychoactive cannabinoids at high doses.”

According to the description, CBD can be ingested in very large amounts without side effects.

“No signs of toxicity or serious side effects have been observed following chronic administration of cannabidiol to healthy volunteers, even in large acute doses of 700mg/day.”

The patent explains that cannabidiol previously had not been considered useful as a neuroprotectant. However, it cites various studies on cannabidiol as an antiepileptic and as a potential treatment for glaucoma.
Does The U.S. Government Own A Patent On Marijuana?

Tech U.S.
— Jul 25, 2014

us-patent-marijuana-07-25
Patent No. 6630507, held by the United States Department of Health and Human Services, covers the use of cannabinoids for treating a wide range of diseases.

Under U.S. federal law, marijuana is defined as having no medical use. So it might come as a surprise to hear that the government owns one of the only patents on marijuana as a medicine.

The patent (US6630507) is titled “Cannabinoids as antioxidants and neuroprotectants” and was awarded to the Department of Health and Human Services (HHS) in October 2003.

It was filed four years earlier, in 1999, by a group of scientists from the National Institute of Mental Health (NIMH), which is part of the National Institutes of Health (NIH).
What is Patent No. 6630507?

us-marijuana-patent-2

The patent claims exclusive rights on the use of cannabinoids for treating neurological diseases, such as Alzheimer’s, Parkinson’s and stroke, and diseases caused by oxidative stress, such as heart attack, Crohn’s disease, diabetes and arthritis.

Cannabinoids are a diverse class of compounds that include many of the unique compounds found in marijuana. A number of experts, including CNN’s chief medical correspondent Dr. Sanjay Gupta, have noted the contradiction between federal marijuana law and the government’s patent.

“The United States government owns a patent on marijuana as a medical application… So we have a patent through our Department of HHS on marijuana as a therapeutic and we also schedule it as a Schedule I.”

It is easy to think of the patent as a patent on marijuana itself. However, this would be inaccurate, since the patent actually covers non-psychoactive cannabinoids (both synthetic and natural), meaning those that don’t cause a high.

The patent also covers only a specific application of these cannabinoids and not the production or use of marijuana and cannabinoids overall.
The Invention

The patent claims to “provide a new class of antioxidant drugs, that have particular application as neuroprotectants.”

According to the description, the inventors recognized “a previously unanticipated antioxidant property of the cannabinoids in general (and cannabidiol in particular).” Importantly, the patent does not cover cannabinoids that act through cannabinoid pathways, also known as receptors.

“This new found property makes cannabinoids useful in the treatment and prophylaxis of wide variety of oxidation associated diseases, such as ischemic, age-related, inflammatory and autoimmune diseases. The cannabinoids are found to have particular application as neuroprotectants, for example in limiting neurological damage following ischemic insults, such as stroke and trauma, or in the treatment of neurodegenerative diseases, such as Alzheimer’s disease, Parkinson’s disease and HIV dementia.”

CBD and Non-Psychoactive Cannabinoids

us-patent-marijuana-3

The government’s patent does not cover THC, the main ingredient in marijuana. On the other hand, cannabidiol (CBD) is specifically mentioned as an example of a cannabinoid that is covered. The patent describes CBD and other non-psychoactive cannabinoids as superior when taken in higher doses.

“Nonpsychoactive cannabinoids, such as cannabidiol, are particularly advantageous to use because they avoid toxicity that is encountered with psychoactive cannabinoids at high doses.”

According to the description, CBD can be ingested in very large amounts without side effects.

“No signs of toxicity or serious side effects have been observed following chronic administration of cannabidiol to healthy volunteers, even in large acute doses of 700mg/day.”

The patent explains that cannabidiol previously had not been considered useful as a neuroprotectant. However, it cites various studies on cannabidiol as an antiepileptic and as a potential treatment for glaucoma.
Does The U.S. Government Own A Patent On Marijuana?

Tech U.S.
— Jul 25, 2014

us-patent-marijuana-07-25
Patent No. 6630507, held by the United States Department of Health and Human Services, covers the use of cannabinoids for treating a wide range of diseases.

Under U.S. federal law, marijuana is defined as having no medical use. So it might come as a surprise to hear that the government owns one of the only patents on marijuana as a medicine.

The patent (US6630507) is titled “Cannabinoids as antioxidants and neuroprotectants” and was awarded to the Department of Health and Human Services (HHS) in October 2003.

It was filed four years earlier, in 1999, by a group of scientists from the National Institute of Mental Health (NIMH), which is part of the National Institutes of Health (NIH).
What is Patent No. 6630507?

us-marijuana-patent-2

The patent claims exclusive rights on the use of cannabinoids for treating neurological diseases, such as Alzheimer’s, Parkinson’s and stroke, and diseases caused by oxidative stress, such as heart attack, Crohn’s disease, diabetes and arthritis.

Cannabinoids are a diverse class of compounds that include many of the unique compounds found in marijuana. A number of experts, including CNN’s chief medical correspondent Dr. Sanjay Gupta, have noted the contradiction between federal marijuana law and the government’s patent.

“The United States government owns a patent on marijuana as a medical application… So we have a patent through our Department of HHS on marijuana as a therapeutic and we also schedule it as a Schedule I.”

It is easy to think of the patent as a patent on marijuana itself. However, this would be inaccurate, since the patent actually covers non-psychoactive cannabinoids (both synthetic and natural), meaning those that don’t cause a high.

The patent also covers only a specific application of these cannabinoids and not the production or use of marijuana and cannabinoids overall.
The Invention

The patent claims to “provide a new class of antioxidant drugs, that have particular application as neuroprotectants.”

According to the description, the inventors recognized “a previously unanticipated antioxidant property of the cannabinoids in general (and cannabidiol in particular).” Importantly, the patent does not cover cannabinoids that act through cannabinoid pathways, also known as receptors.

“This new found property makes cannabinoids useful in the treatment and prophylaxis of wide variety of oxidation associated diseases, such as ischemic, age-related, inflammatory and autoimmune diseases. The cannabinoids are found to have particular application as neuroprotectants, for example in limiting neurological damage following ischemic insults, such as stroke and trauma, or in the treatment of neurodegenerative diseases, such as Alzheimer’s disease, Parkinson’s disease and HIV dementia.”

CBD and Non-Psychoactive Cannabinoids

us-patent-marijuana-3

The government’s patent does not cover THC, the main ingredient in marijuana. On the other hand, cannabidiol (CBD) is specifically mentioned as an example of a cannabinoid that is covered. The patent describes CBD and other non-psychoactive cannabinoids as superior when taken in higher doses.

“Nonpsychoactive cannabinoids, such as cannabidiol, are particularly advantageous to use because they avoid toxicity that is encountered with psychoactive cannabinoids at high doses.”

According to the description, CBD can be ingested in very large amounts without side effects.

“No signs of toxicity or serious side effects have been observed following chronic administration of cannabidiol to healthy volunteers, even in large acute doses of 700mg/day.”

The patent explains that cannabidiol previously had not been considered useful as a neuroprotectant. However, it cites various studies on cannabidiol as an antiepileptic and as a potential treatment for glaucoma.



Edited 1 time(s). Last edit at 01/04/2017 01:22AM by riverhousebill.

How State Initiatives to Legalize Marijuana for Recreational Use Can End Up Banning Medical Cannabis

While recent state initiatives to legalize the recreational use of marijuana are often seen as a step in the right direction to make medical cannabis more available to those who need it, these new laws, and along with them new federal regulations, are in fact doing just the opposite in some cases, particularly in Washington State.

State level medical cannabis programs are being deterred and even being shut down by plans to legalize the recreational use of cannabis. In Washington State, a popular vote of the people approved the legalization of marijuana and the creation of a licensed system of growers, processors, and retailers. As originally intended, the new distribution system for recreational marijuana was to coexist with the system for growing and distribution of medical cannabis.

But as it turns out, the medical cannabis system is being folded into the newly approved system for legal marijuana sales. This new structure will have the effect of dismantling what had been an effective medical distribution system for medical cannabis in that state. The medical cannabis program was criticized for its loose regulation, even though the distribution network was working well to serve the needs of patients. Why did the state decide to merge the two systems?

The Seattle Times describes the motivation behind reforming the existing medical marijuana law.

“Lawmakers have worried that the largely unregulated medical system would undercut the taxed recreational industry established by Initiative 502. U.S. Justice Department officials have warned that the state’s medical pot status quo is untenable. … State Senator Ann Rivers has said she’s sympathetic to patients’ concerns, but she’s worried about what the federal government will do if the state doesn’t make the changes.21

The new law will reduce the amount of the drug that patients can possess or grow, eliminate collective gardens (which many dispensaries use), require medical users to register with the state, and mandate that both medical cannabis and recreational marijuana only be sold by the new licensed retailers.

“Trusted dispensaries will be closed, they contend, and choices will diminish, with the varieties that marijuana medical users prefer squeezed off the shelves by more profitable recreational varieties grown for their greater, high-producing THC content, not for headache or nausea relief. In Seattle alone, about 200 dispensaries will have to close, replaced by 21 licensed retailers, and under current state regulations, employees in those shops will not be allowed to even discuss the medical value of the products for sale.”22

According to The Washington State Liquor Control Board, the new law for recreational marijuana will produce substantial income for the state. Estimated income could be as high as $2 billion dollars during the first five years. The rate of taxation will be substantial. The initiative applies a 25% excise tax on each level of the system: producer to a processor, processor to a retailer, and retailer to the customer. In addition, B&O taxes on the production and local retail sales taxes apply. The markup for the stages of production will also be substantial. The Fiscal Impact Statement from the OFM places a price estimate of a $3 per gram producer price, a $6 per gram processor price and a pre-tax $12 per gram average retail purchase price.23

TAXES AND DEATH YOUR RIGHTS BE SILENT CONSUME THEN DIE



Edited 1 time(s). Last edit at 01/05/2017 02:43AM by riverhousebill.